Thought LeadersLiam O’Mahony, Barry Skillington & John MacSharryProf. of Immunology, Cheif Commerical Officer & Research PartnerAtlantia and Clinical Trials Though most people know that their immune system is supported by microbes, the complexity and interrelation between the body’s microbial changes and wider health is something known only to those in the field.
With over half the cells in the human body being bacterial rather than human, and over 99% of the genes in the human body being microbial encoded, medical microbiology is an essential component of future healthcare – and two of the principal areas of study are the gut and the lung.
Clinical trials from Atlantia support human immunity by investigating the impact that microbes have on future health and immune regulation. Bacterial-induced immune regulation has significant indications for potential developments in healthcare, including new treatment and diet possibilities for the regulation of afflictions such as allergies and asthma.
Three experts – Dr. Liam O’Mahony, Dr. John MacSharry and Dr. Barry Skillington – were interviewed in conjunction with Atlantia Food Clinical Trials to discuss microbial interactions with host immune systems, specifically relating to the gut microbiome, the lung microbiome, and an overview of clinical trials within the immunity among other areas.
Please could you introduce yourselves and outline your roles?
BS: My name is Barry Skillington, and I am the Chief Commercial Officer here with Atlantia Food Clinical Trials.
LOM: I am Liam O’Mahony, and I am the Professor of Immunology at the Department of Medicine and Microbiology,